Related Experiment Video

Updated: Jan 18, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.1K

The opposite effects of angiotensin 1-9 and angiotensin 3-7 in prostate epithelial cells

Kamila Domińska1, Karolina Kowalska2, Dominika Ewa Habrowska-Górczyńska2

  • 1Department of Comparative Endocrinology, Medical University of Lodz, Lodz, 90-752, Poland.

Biochemical and Biophysical Research Communications
|September 30, 2019
PubMed

Insights

Angiotensin-1-9 (Ang1-9) promotes prostate cancer cell growth and migration, while Angiotensin-3-7 (Ang3-7) inhibits these processes. Further research is needed to identify the specific angiotensin receptors involved.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Renin-angiotensin system (RAS) components are implicated in cancer development, including prostate cancer.
  • Specific angiotensin peptides' roles in prostate cancer are not fully understood.

Purpose of the Study:

  • To investigate the effects of Angiotensin-1-9 (Ang1-9) and Angiotensin-3-7 (Ang3-7) on prostate epithelial cell viability, proliferation, migration, and invasion.
  • To explore the impact of these peptides on gene expression related to cancer progression and angiotensin receptors.

Main Methods:

  • In vitro studies on prostate epithelial cells (PNT1A).
  • Assays for cell viability, proliferation, migration, and invasion.
  • Quantitative analysis of gene expression for vascular endothelial growth factor (VEGF), hypoxia-inducible factors (HIF-1), vimentin (VIM), REL proto-oncogene (REL), and angiotensin receptors.

Main Results:

  • Ang1-9 demonstrated pro-cancer effects, increasing cell division, motility, and expression of VEGF, HIF-1, VIM, and REL.
  • Ang3-7 exhibited no mitogenic activity and inhibited PNT1A cell migration, likely by downregulating VEGF and VIM.
  • Both peptides modulated gene expression for angiotensin receptors, but the specific receptor involved in PNT1A cell signaling remains unidentified.

Conclusions:

  • Ang1-9 and Ang3-7 have opposing effects on prostate cancer cell behavior in vitro.
  • Ang1-9 may promote prostate cancer progression, whereas Ang3-7 might have inhibitory effects.
  • Further investigation is required to elucidate the specific angiotensin receptor pathways mediating these effects in prostate cancer.
Keywords:
AngiotensinCell invasionCell proliferationEpithelial-mesenchymal transitionNF-κB membersProstate

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

11.6K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
943
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.9K